| Active ingredients | Dosage form | Quantity of active ingredients | Shortage status | Availability | Reason | Last updated |
| siponimod hemifumarate | Tablet, film coated | .278 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 15/09/2024 |
| adrenaline (epinephrine) | Injection, solution | 1 mg | Current | Limited Availability | Manufacturing | 13/09/2024 |
| isoniazid | Tablet, uncoated | 100 mg | Current | Unavailable | Manufacturing | 13/09/2024 |
| pentetic acid | Injection, powder for | 5 mg | Anticipated | Available | Manufacturing | 13/09/2024 |
| sodium pyrophosphate | Injection, powder for | 30 mg | Anticipated | Available | Manufacturing | 13/09/2024 |
| Pancreatic extract | Capsule, enteric | 150 mg | Current | Limited Availability | Unexpected increase in consumer demand | 13/09/2024 |
| methotrexate | Injection, solution | 100 mg/mL | Anticipated | Available | Manufacturing | 13/09/2024 |
| acetylcysteine | Injection, concentrated | 2 g | Anticipated | Available | Transport / Logistic issues / Storage capacity issues | 13/09/2024 |
| ezetimibe~rosuvastatin calcium | Tablet~Tablet, film coated | 10 mg~20.791 mg | Current | Limited Availability | Manufacturing | 13/09/2024 |
| quetiapine fumarate | Tablet, film coated | 28.784 mg | Current | Limited Availability | Unexpected increase in consumer demand | 13/09/2024 |
| simvastatin | Tablet, film coated | 40 mg | Anticipated | Available | Manufacturing | 13/09/2024 |
| acarbose | Tablet | 50 mg | Current | Unavailable | Manufacturing | 13/09/2024 |
| hydrochlorothiazide~irbesartan | Tablet, film coated | 25 mg~300 mg | Anticipated | Available | Manufacturing | 13/09/2024 |
| lurasidone hydrochloride | Tablet, film coated | 80 mg | Anticipated | Available | Manufacturing | 13/09/2024 |
| mycophenolate mofetil | Injection, powder for | 500 mg | Resolved | Available | Manufacturing | 13/09/2024 |
| oseltamivir phosphate | Capsule, hard | 98.524 mg | Anticipated | Available | Unexpected increase in consumer demand | 13/09/2024 |
| flucloxacillin sodium monohydrate | Injection, powder for | 1088.1 mg | Resolved | Available | Transport / Logistic issues / Storage capacity issues | 13/09/2024 |
| methylphenidate hydrochloride | Tablet, modified release | 27 mg | Anticipated | Available | Manufacturing | 13/09/2024 |
| phenytoin sodium | Injection, solution | 100 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 13/09/2024 |
| rifabutin | Capsule, hard | 150 mg | Anticipated | Available | Manufacturing | 13/09/2024 |
| amoxicillin trihydrate | Oral Liquid, powder for | 114.82 mg/mL | Current | Unavailable | Manufacturing | 13/09/2024 |
| clarithromycin | Tablet, film coated | 250 mg | Anticipated | Available | Unexpected increase in consumer demand | 13/09/2024 |
| primidone | Tablet, uncoated | 250 mg | Current | Limited Availability | Manufacturing | 12/09/2024 |
| topiramate | Tablet, film coated | 200 mg | Anticipated | Available | Manufacturing | 12/09/2024 |
| morphine hydrochloride trihydrate | Oral Liquid, solution | 2 mg/mL | Current | Unavailable | Commercial Changes / Commercial viability | 12/09/2024 |
| morphine hydrochloride trihydrate | Oral Liquid, solution | 5 mg/mL | Current | Unavailable | Commercial Changes / Commercial viability | 12/09/2024 |
| morphine hydrochloride trihydrate | Oral Liquid, solution | 10 mg/mL | Current | Unavailable | Commercial Changes / Commercial viability | 12/09/2024 |
| olanzapine | Tablet, orally disintegrating | 20 mg | Anticipated | Available | Manufacturing | 12/09/2024 |
| mycophenolate mofetil | Tablet, film coated | 500 mg | Current | Limited Availability | Manufacturing | 12/09/2024 |
| omeprazole | Capsule | 20 mg | Current | Limited Availability | Manufacturing | 12/09/2024 |
| adrenaline (epinephrine) acid tartrate | Injection, solution | 182 microgram/mL | Current | Unavailable | Manufacturing | 12/09/2024 |
| simvastatin | Tablet, film coated | 10 mg | Anticipated | Available | Manufacturing | 12/09/2024 |
| citalopram hydrobromide | Tablet, film coated | 49.98 mg | Anticipated | Available | Manufacturing | 12/09/2024 |
| atorvastatin calcium trihydrate | Tablet, film coated | 86.76 mg | Current | Limited Availability | Manufacturing | 12/09/2024 |
| nebivolol hydrochloride | Tablet | 1.363 mg | Anticipated | Available | Manufacturing | 12/09/2024 |
| acamprosate calcium | Tablet, enteric coated | 333 mg | Anticipated | Available | Manufacturing | 12/09/2024 |
| ezetimibe~atorvastatin calcium trihydrate | Tablet, film coated | 10 mg~41.363 mg | Current | Unavailable | Manufacturing | 12/09/2024 |
| atorvastatin calcium trihydrate~ezetimibe | Tablet, film coated | 20.681 mg~10 mg | Current | Unavailable | Manufacturing | 12/09/2024 |
| ezetimibe~atorvastatin calcium trihydrate | Tablet, film coated | 10 mg~82.725 mg | Current | Unavailable | Manufacturing | 12/09/2024 |
| lanreotide acetate | Injection, solution | 133.33 mg | Current | Unavailable | Transport / Logistic issues / Storage capacity issues | 12/09/2024 |
| sitagliptin hydrochloride monohydrate | Tablet, film coated | 27.25 mg | Current | Unavailable | Manufacturing | 12/09/2024 |
| aciclovir | Injection, solution | 25 mg/mL | Current | Unavailable | Manufacturing | 12/09/2024 |
| tobramycin | Inhalation, conventional | 60 mg/mL | Current | Unavailable | Manufacturing | 12/09/2024 |
| amoxicillin sodium | Injection, powder for | 1060 mg | Anticipated | Available | Manufacturing | 12/09/2024 |
| metoprolol succinate | Tablet, modified release | 47.5 mg | Anticipated | Available | Manufacturing | 11/09/2024 |
| metoprolol succinate | Tablet, modified release | 190 mg | Anticipated | Available | Manufacturing | 11/09/2024 |
| metoprolol succinate | Tablet, modified release | 95 mg | Anticipated | Available | Manufacturing | 11/09/2024 |
| bisoprolol fumarate | Tablet | 2.5 mg | Current | Unavailable | Manufacturing | 11/09/2024 |
| bisoprolol fumarate | Tablet | 5 mg | Current | Unavailable | Manufacturing | 11/09/2024 |
| duloxetine hydrochloride | Capsule, enteric | 33.65 mg | Current | Unavailable | Manufacturing | 11/09/2024 |
| duloxetine hydrochloride | Capsule, enteric | 67.3 mg | Current | Unavailable | Manufacturing | 11/09/2024 |
| citalopram hydrobromide | Tablet, film coated | 12.495 mg | Anticipated | Available | Manufacturing | 11/09/2024 |
| ezetimibe | Tablet, uncoated | 10 mg | Current | Unavailable | Manufacturing | 11/09/2024 |
| ezetimibe | Tablet | 10 mg | Current | Unavailable | Unexpected increase in consumer demand | 11/09/2024 |
| ezetimibe | Tablet | 10 mg | Current | Unavailable | Unexpected increase in consumer demand | 11/09/2024 |
| tadalafil | Tablet, film coated | 20 mg | Current | Limited Availability | Manufacturing | 11/09/2024 |
| tadalafil | Tablet, film coated | 10 mg | Anticipated | Available | Manufacturing | 11/09/2024 |
| nebivolol hydrochloride | Tablet | 10.9 mg | Current | Unavailable | Manufacturing | 11/09/2024 |
| nizatidine | Capsule, hard | 150 mg | Current | Unavailable | Manufacturing | 11/09/2024 |
| dasatinib | Tablet, film coated | 100 mg | Current | Limited Availability | Manufacturing | 11/09/2024 |
| ropinirole hydrochloride | Tablet, film coated | 2.28 mg | Resolved | Available | Manufacturing | 11/09/2024 |
| linezolid | Tablet, film coated | 600 mg | Current | Limited Availability | Unexpected increase in consumer demand | 11/09/2024 |
| lacosamide | Tablet, film coated | 50 mg | Anticipated | Available | Manufacturing | 11/09/2024 |
| spironolactone | Tablet, uncoated | 100 mg | Current | Limited Availability | Manufacturing | 11/09/2024 |
| cisplatin | Injection, solution | 1 mg/mL | Current | Limited Availability | Unexpected increase in consumer demand | 11/09/2024 |
| nizatidine | Capsule, hard | 300 mg | Current | Unavailable | Manufacturing | 11/09/2024 |
| paclitaxel | Injection, concentrated | 6 mg/mL | Resolved | Available | Manufacturing | 11/09/2024 |
| baclofen | Tablet, uncoated | 25 mg | Current | Unavailable | Transport / Logistic issues / Storage capacity issues | 11/09/2024 |
| escitalopram oxalate | Tablet, film coated | 25.56 mg | Current | Limited Availability | Manufacturing | 10/09/2024 |
| dexamethasone~framycetin sulfate~gramicidin | Ear Drops | .5 mg/mL~5 mg/mL~.05 mg/mL | Current | Unavailable | Manufacturing | 10/09/2024 |
| risperidone | Tablet | .5 mg | Resolved | Available | Manufacturing | 10/09/2024 |
| risperidone | Tablet | 1 mg | Resolved | Available | Manufacturing | 10/09/2024 |
| gabapentin | Tablet, film coated | 800 mg | Current | Unavailable | Manufacturing | 10/09/2024 |
| hydrocortisone sodium succinate | Injection, powder for | 134 mg | Resolved | Available | Manufacturing | 10/09/2024 |
| duloxetine hydrochloride | Capsule, enteric | 67.3 mg | Current | Limited Availability | Manufacturing | 10/09/2024 |
| duloxetine hydrochloride | Capsule, enteric | 33.65 mg | Resolved | Available | Manufacturing | 10/09/2024 |
| hydrochlorothiazide~telmisartan | Tablet, film coated | 12.5 mg~80 mg | Current | Limited Availability | Manufacturing | 10/09/2024 |
| duloxetine hydrochloride | Capsule, enteric | 33.66 mg | Current | Unavailable | Unexpected increase in consumer demand | 10/09/2024 |
| amlodipine besilate | Tablet | 13.87 mg | Resolved | Available | Manufacturing | 10/09/2024 |
| ezetimibe | Tablet, uncoated | 10 mg | Resolved | Available | Unexpected increase in demand due to other sponsors unable to supply | 10/09/2024 |
| ezetimibe | Tablet | 10 mg | Current | Unavailable | Manufacturing | 10/09/2024 |
| ezetimibe | Tablet, uncoated | 10 mg | Current | Unavailable | Transport / Logistic issues / Storage capacity issues | 10/09/2024 |
| ezetimibe | Tablet, uncoated | 10 mg | Current | Limited Availability | Manufacturing | 10/09/2024 |
| clonidine hydrochloride | Tablet | 100 microgram | Current | Unavailable | Unexpected increase in consumer demand | 10/09/2024 |
| cinacalcet hydrochloride | Tablet, film coated | 33 mg | Resolved | Available | Manufacturing | 10/09/2024 |
| tenofovir disoproxil fumarate | Tablet | 300 mg | Current | Unavailable | Manufacturing | 10/09/2024 |
| ezetimibe~simvastatin | Tablet | 10 mg~20 mg | Resolved | Available | Manufacturing | 10/09/2024 |
| mesalazine | Tablet, enteric coated | 1.6 g | Current | Unavailable | Transport / Logistic issues / Storage capacity issues | 10/09/2024 |
| bendamustine hydrochloride monohydrate | Injection, powder for | 100 mg | Current | Unavailable | Unexpected increase in demand due to other sponsors unable to supply | 10/09/2024 |
| rosuvastatin calcium | Tablet, film coated | 5.21 mg | Resolved | Available | Manufacturing | 10/09/2024 |
| dosulepin (dothiepin) hydrochloride | Capsule, hard | 25 mg | Current | Unavailable | Manufacturing | 10/09/2024 |
| indometacin | Capsule, hard | 25 mg | Current | Limited Availability | Manufacturing | 10/09/2024 |
| temozolomide | Capsule, hard | 5 mg | Current | Limited Availability | Manufacturing | 10/09/2024 |
| methylphenidate hydrochloride | Tablet, modified release | 18 mg | Current | Unavailable | Manufacturing | 10/09/2024 |
| lanreotide acetate | Injection, solution | 100 mg | Current | Unavailable | Transport / Logistic issues / Storage capacity issues | 10/09/2024 |
| sitagliptin hydrochloride monohydrate | Tablet, film coated | 109 mg | Current | Unavailable | Manufacturing | 10/09/2024 |
| sitagliptin hydrochloride monohydrate | Tablet, film coated | 54.5 mg | Current | Unavailable | Manufacturing | 10/09/2024 |
| ezetimibe~rosuvastatin calcium | Tablet | 10 mg~10.4 mg | Current | Unavailable | Manufacturing | 10/09/2024 |
| ezetimibe~rosuvastatin calcium | Tablet~Tablet, film coated | 10 mg~41.6 mg | Current | Limited Availability | Manufacturing | 10/09/2024 |
| ezetimibe~rosuvastatin calcium | Tablet~Tablet, film coated | 10 mg~20.8 mg | Current | Unavailable | Manufacturing | 10/09/2024 |
| ezetimibe | Tablet | 10 mg | Current | Unavailable | Manufacturing | 10/09/2024 |
| heparin sodium | Injection, solution | 5000 IU/mL | Anticipated | Available | Manufacturing | 10/09/2024 |
| clarithromycin | Oral Liquid, powder for | 50 mg/mL | Current | Limited Availability | Unexpected increase in consumer demand | 10/09/2024 |
| azithromycin dihydrate | Suspension, powder for | 209.65 mg | Current | Unavailable | Unexpected increase in consumer demand | 10/09/2024 |
| indapamide hemihydrate | Tablet | 2.5 mg | Current | Limited Availability | Manufacturing | 10/09/2024 |
| salbutamol sulfate | Inhalation | 1.2 mg/mL | Resolved | Available | Manufacturing | 9/09/2024 |
| fentanyl | Drug delivery system, transdermal | 2.063 mg | Discontinued | Unavailable | Commercial Changes / Commercial viability | 9/09/2024 |
| fentanyl | Drug delivery system, transdermal | 8.25 mg | Discontinued | Unavailable | Commercial Changes / Commercial viability | 9/09/2024 |
| fentanyl | Drug delivery system, transdermal | 12.375 mg | Discontinued | Unavailable | Commercial Changes / Commercial viability | 9/09/2024 |
| galantamine hydrobromide | Capsule, modified release | 20.512 mg | Resolved | Available | Manufacturing | 9/09/2024 |
| hydrocortisone sodium succinate | Injection, powder for | 334.25 mg | Current | Limited Availability | Manufacturing | 9/09/2024 |
| bosentan monohydrate | Tablet, film coated | 64.541 mg | Resolved | Available | Manufacturing | 9/09/2024 |
| midazolam | Injection, solution | 5 mg/mL | Current | Limited Availability | Manufacturing | 9/09/2024 |
| midazolam | Injection, solution | 1 mg/mL | Anticipated | Available | Manufacturing | 9/09/2024 |
2024年9月17日